Antibodies

Functional Assay

Neutralisation/Blocking

Applications

Human

Host

AdipoGen Life Sciences

Supplier

Monoclonal

Clonality

IgG1

Isotype

Research Use Only

Certification

Business Unit

anti-Zika Virus Envelope Protein (EIII domain), mAb (rec.) (neutralizing) (ZKA64) (preservative free) for Functional Assay, Blocking in Virus.

AG-27B-6004PF anti-Zika Virus Envelope Protein (EIII domai...

anti-Zika Virus Envelope Protein (EIII domain), mAb (rec.) (neutralizing) (ZKA64) (preservative free)

Recombinant Antibody. Recognizes and binds specifically to the EDIII domain of the Zika Virus envelope protein (ZIKV E). It does not cross-react with Dengue virus envelope protein (DENV E). Species cross-reactivity: Virus. Clone: ZKA64. Isotype: Human IgG1kappa. Applications: FUNC, FUNC (Blocking). Host: . Liquid. In PBS. The main route of Zika Virus (ZIKV) infection is through bites by Aedes mosquitos, but the virus may also be sexually and vertically transmitted. Although most of the ZIKV infections are asymptomatic or cause only mild symptoms, there is evidence that ZIKV infection can lead to neurological complications, such as Guillain-Barre syndrome in adults and congenital birth defects, including microcephaly in the developing fetus, likely through its ability to infect human neural progenitor cells. Whereas flavivirus envelope (E) proteins mediate fusion and are the main target of neutralizing antibodies, the non-structural protein 1 (NS1) is secreted by infected cells and is involved in immune evasion and pathogenesis. The E protein contains three domains: EDI involved in the conformational changes required for viral entry; EDII containing the fusion loop; and EDIII which may be involved in binding to cellular receptors. The best specific neutralizing antibodies to ZIKV are directed against the domain EDIII of ZIKV. - The main route of Zika Virus (ZIKV) infection is through bites by Aedes mosquitos, but the virus may also be sexually and vertically transmitted. Although most of the ZIKV infections are asymptomatic or cause only mild symptoms, there is evidence that ZIKV infection can lead to neurological complications, such as Guillain-Barre syndrome in adults and congenital birth defects, including microcephaly in the developing fetus, likely through its ability to infect human neural progenitor cells. Whereas flavivirus envelope (E) proteins mediate fusion and are the main target of neutralizing antibodies, the non-structural protein 1 (NS1) is secreted by infected cells and is involved in immune evasion and pathogenesis. The E protein contains three domains: EDI involved in the conformational changes required for viral entry; EDII containing the fusion loop; and EDIII which may be involved in binding to cellular receptors. The best specific neutralizing antibodies to ZIKV are directed against the domain EDIII of ZIKV.

Website

Events

Promotions

Our company

Our team

For suppliers

Vacatures

About us

Headquarters

Customer Service

Technical support

Accountmanagers

Contact

Our people

Chemicals

Proteins / Signaling Molecules

Assays

(Cell) Culture

Products

Our Company

Suppliers

Divisions

News

Bio-Connect

Biotech, Pharma & CRO

Academia

Diagnostics

Environment

Food

Veterinary

Industries

Disclaimer

Privacy Statement

Terms and conditions

Are you looking for specific products, alternatives, documentation or need assistance with solving product related issues? Let our in-house technical support team help you.

We support your research

<p>For 15 years, we connect life science researchers specialized in the import and distribution of life science reagents from global suppliers.</p>

Support your research

DNA / RNA / Vectors

Cell Culture

Genome Editing and Engineering

Molecular Biology

Lysates / Extracts

Expression

Labware / Accesories

Body Products

Technique Specific Products

Arrays / Slides

Diagnostic

Biologicals

Life Sciences

Services

Become a partner

Call +31 (0)26 326 44 50

Search results: AG-27B-6004PF

Didn't find what you were looking for?